Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 7, 2002, Pages 351-359

  Baron, F ^a   Beguin, Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Graft versus host disease; Graft versus leukemia effect; Preemptive donor lymphocyte infusion; T cell depletion

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; CONTROLLED STUDY; DONOR; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; LEUKEMIA; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFER; MYELODYSPLASTIC SYNDROME; RECIPIENT; REVIEW; SIDE EFFECT; T LYMPHOCYTE;

EID: 0036051757     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12171481     Document Type: Article

References (98)

1. Acute graft-vs-host disease: Pathobiology and management
2. Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment
3. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: An update
4. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
5. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias
6. Pathophysiologic mechanisms of acute graft-versus-host disease
7. Pathogenesis of acute graft-versus-host disease: Cytokines and cellular effectors
8. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion
9. T-cell depletion of HLA-identical transplants in leukemia
10. Evolving strategies to address adverse transplant outcomes associated with T cell depletion
11. Donor lymphocyte infusion: The use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation
12. The benefits of an alloresponse: Graft-versus-tumor
13. Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease
14. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia
15. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
16. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation
17. Infusion of donor lymphocytes to eradicate recurrent host hematopoiesis after allogeneic bone marrow transplantation for sickle cell disease
18. Adoptive immunotherapy: Insights from donor lymphocyte infusions
19. The graft-versus-tumor potential of allogeneic cell therapy: An update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation
20. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia
21. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse
22. Treatment of leukaemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571
23. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: The case for giving donor leucocyte transfusion before the onset of hematologic relapse
24. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation
25. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
26. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect
27. Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation
28. Allogeneic peripheral blood stem cell transplantation with CD34-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study
29. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect
30. Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions
31. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back
32. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation
33. T-cell depletion in allogeneic bone marrow transplantation: Progress and problems
34. Allogeneic blood stem cell transplantation: Peripheralization and yield of donorderived primitive hematopoietic progenitor cells (CD34+ Thy1dim) and lymphoid subsets, and possible predictors of engraftment and disease
35. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy
36. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood
37. A laboratory comparison of T cell depletion by CD34+ cell inummoaffinity selection and in vitro Campath-1M treatment: Clinical implications for bone marrow transplantation and donor leukocyte therapy
38. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia
39. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation
40. Transplantation of anergic histoincompatible bone marrow allografts
41. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
42. Allogeneic cell therapy: The treatment of choice for all hematologic malignancies relapsing post BMT
43. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions
44. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
45. Adoptive immunotherapy with donor lymphocyte transfusions
46. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient
47. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells
48. Leukemic target susceptibility to natural killer cytotoxicity: Relationship with BCR-ABL expression
49. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma
50. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: Impact of infused and residual donor T cells
51. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
52. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
53. Donor lymphocyte infusion for post-transplant relapse of Hodgkin's lymphoma
54. Chronic graft-versus-host disease
55. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
56. Non-myeloablative stem cell transplants
57. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
58. Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation
59. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
60. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
61. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse
62. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation
63. Cytokine dysregulation and acute graft-versus-host disease
64. The role of cytokines in acute graft-versus-host disease
65. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
66. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
67. Lymphohematopoietic graft-versus-host reactions can be induced without graft-versus-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen
68. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies
69. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation
70. Induction of tolerance by mixed chimerism with nonmyeloblative host conditioning: The importance of overcoming intrathymic alloresistance
71. Protection from graft-versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow
72. Adoptive immunotherapy in canine chimeras
73. A randomized trial of CD8+ T cell depletion to prevent graft-vs-host disease (GVHD) associated with donor lymphocyte infusions
74. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
75. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia
76. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune response
77. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL
78. Mixed chimerism: Preclinical studies and clinical applications
79. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
80. Non-myeloablative transplants for malignant disease
81. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
82. Nonmyeloablative allogeneic hematopoietic stem cell transplantation
83. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease
84. Nonmyeloablative stem cell transplantation (NMSCT) with CD8-depleted or CD34-selected PBSC
85. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
86. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of genemodified virus-specific T lymphocytes
87. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBY-associated lymphoproliferative disease
88. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation
89. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution
90. Feasibility of immunotherapy of relapsed leukemia with ex vivo generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
91. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients
92. Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia
93. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
94. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1
95. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation
96. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia reactive cytotoxic T lymphocytes
97. Specific T cell therapy in leukemia
98. Graft-versus-leukemia reactions after bone marrow transplantation